Kibra knockdown inhibits the aberrant Hippo pathway, suppresses renal cyst formation and ameliorates renal fibrosis in nphp1^KO mice

Abstract

	•Canonical Hippo pathway activated in nphp1-deficient disease models and patients.
	•Kibra was a key upstream molecule in regulating the activation of canonical Hippo pathway in nphp1-deficient disease models and patients and closely related to renal cyst formation and fibrosis in nphp1KO mice.

Keywords

Hippo pathway / Kibra / nephronophthisis / nphp1 / renal cyst

References

[1] Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27(3):363-373.

[2] Srivastava S, Molinari E, Raman S, Sayer JA. Many genes—one disease? Genetics of nephronophthisis (NPHP) and NPHP-associated disorders. Front Pediatr. 2018;5:287.

[3] Gupta S, Ozimek-Kulik JE, Phillips JK. Nephronophthisis – pathobiology and molecular pathogenesis of a rare kidney genetic disease. Genes (Basel). 2021;12(11):1762.

[4] Petzold F, Billot K, Chen X, et al. The genetic landscape and clinical spectrum of nephronophthisis and related ciliopathies. Kidney Int. 2023;104(2):378-387.

[5] Wolf MTF, Hildebrandt F. Nephronophthisis. Pediatr Nephrol. 2011;26(2):181-194.

[6] Simms RJ, Eley L, Sayer JA. Nephronophthisis. Eur J Hum Genet. 2009;17(4):406-416.

[7] Sang L, Miller JJ, Corbit KC, et al. Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. Cell. 2011;145(4):513-528.

[8] Ishikawa H, Marshall WF. Ciliogenesis: building the cell’s antenna. Nat Rev Mol Cell Biol. 2011;12(4):222-234.

[9] Anvarian Z, Mykytyn K, Mukhopadhyay S, Pedersen LB, Christensen ST. Cellular signalling by primary cilia in development, organ function and disease. Nat Rev Nephrol. 2019;15(4):199-219.

[10] Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development. 1995;121(4):1053-1063.

[11] Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene Warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9(5):534-546.

[12] Dong J, Feldmann G, Huang J et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120-1133.

[13] Zhao B, Ye X, Yu J et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962-1971.

[14] Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol. 2008;18(5):311-321.

[15] Hergovich A, Schmitz D, Hemmings BA. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem Biophys Res Commun. 2006;345(1):50-58.

[16] Chan EH, Nousiainen M, Chalamalasetty RB et al. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24(12):2076-2086.

[17] Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010;24(1):72-85.

[18] Kanai F, Marignani PA, Sarbassova D, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000;19(24):6778-6791.

[19] Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747-2761.

[20] Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell. 2005;122(3):421-434.

[21] Pocaterra A, Romani P, Dupont S. YAP/TAZ functions and their regulation at a glance. J Cell Sci. 2020;133(2):jcs230425.

[22] Yu J, Zheng Y, Dong J, et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell. 2010;18(2):288-299.

[23] Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell. 2010;18(2):300-308.

[24] Qi S, Zhu Y, Liu X, et al. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Mol Cell. 2022;82(10):1850-1864.

[25] Morin-Kensicki EM, Boone BN, Howell M, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 2006;26(1):77-87.

[26] Reginensi A, Scott RP, Gregorieff A, et al. Yap-and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet. 2013;9(3):e1003380.

[27] Hossain Z, Ali SM, Ko HL, et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A. 2007;104(5):1631-1636.

[28] Tian Y, Kolb R, Hong JH, et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol. 2007;27(18):6383-6395.

[29] Habbig S, Bartram MP, Müller RU, et al. NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol. 2011;193(4):633-642.

[30] Habbig S, Bartram MP, Sagmuller JG, et al. The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ. Hum Mol Genet. 2012;21(26):5528-5538.

[31] Frank V, Habbig S, Bartram MP, et al. Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression. Hum Mol Genet. 2013;22(11):2177-2185.

[32] Airik M, Schüler M, McCourt B, et al. Loss of Anks6 leads to YAP deficiency and liver abnormalities. Hum Mol Genet. 2020;29(18):3064-3080.

[33] CHEN Huamu SLHM. Construction of NPHP1 knockout renal collecting ductepithelial cells based on CRISPR/Cas9 technology. Shandong Med J. 2020;60(17):21-25, 115.

[34] Wu X, Wang H, Chen H, et al. Overexpression of smad7 inhibits the TGF-β/Smad signaling pathway and EMT in NPHP1-defective MDCK cells. Biochem Biophys Res Commun. 2021;582:57-63.

[35] Hu Q, Lai J, Chen H, et al. Reducing GEF-H1 expression inhibits renal cyst formation, inflammation, and fibrosis via RhoA signaling in nephronophthisis. Int J Mol Sci. 2023;24(4):3504.

[36] Li D, Hu M, Chen H, et al. An Nphp1 knockout mouse model targeting exon 2–20 demonstrates characteristic phenotypes of human nephronophthisis. Hum Mol Genet. 2021;31(2):232-243.

[37] Schwarz H, Popp B, Airik R, et al. Biallelic ANKS6 mutations cause late-onset ciliopathy with chronic kidney disease through YAP dysregulation. Hum Mol Genet. 2022;31(9):1357-1369.

[38] Muller RU, Schermer B. Hippo signaling-a central player in cystic kidney disease? Pediatr Nephrol. 2020;35(7):1143-1152.

[39] Delous M, Hellman NE, Gaudé H, et al. Nephrocystin-1 and nephrocystin-4 are required for epithelial morphogenesis and associate with PALS1/PATJ and Par6. Hum Mol Genet. 2009;18(24):4711-4723.

[40] Wolf MT. Nephronophthisis and related syndromes. Curr Opin Pediatr. 2015;27(2):201-211.

[41] Ben MS, Mauviel A. Molecular mechanisms underlying TGF-ss/Hippo signaling crosstalks—role of baso-apical epithelial cell polarity. Int J Biochem Cell Biol. 2018;98:75-81.

[42] Duning K, Schurek EM, Schluter M, et al. KIBRA modulates directional migration of podocytes. J Am Soc Nephrol. 2008;19(10):1891-1903.

[43] Zhang Y, Zhang Y, Kameishi S, et al. The Amot/Integrin protein complex transmits mechanical forces required for vascular expansion. Cell Rep. 2021;36(8):109616.

[44] Wang W, Li X, Huang J, et al. Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics. 2014;13(1):119-131.

[45] Meliambro K, Wong JS, Ray J, et al. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics. J Biol Chem. 2017;292(51):21137-21148.

[46] Meliambro K, Yang Y, de Cos M, et al. KIBRA upregulation increases susceptibility to podocyte injury and glomerular disease progression. JCI Insight. 2023;8(7):e165002.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.